Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T18:58:43.946Z.
Calculation as of: 2026-10-06T18:58:43.946Z.
Quote observation: 2026-10-06T18:51:49.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2d4dff4c736cbb4e00c259d8a24cf863f8d27a03b54b82d918c664c72978b9aa
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Senti Biosciences, Inc.
Market Cap
$10.58M
Price/FCF Ratio
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO |
|---|---|---|
| Senti Biosciences, Inc. (SNTI) | $10.58M | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.51M | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $10.41M | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.37M | N/A |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.18M | N/A |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.10M | N/A |
| Pluri Inc. (PLUR)vs › | $10.79M | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.22M | N/A |
| Caring Brands, Inc. (CABR)vs › | $10.82M | N/A |
| Valion Bio, Inc. (VBIO)vs › | $9.88M | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
